Travoprost
Pronunciation: (tra-voe-prost)Class: Prostaglandin agonist
Trade Names:
Travatan
- Solution 0.004%
Pharmacology
 | |||||||||
 User Reviews & Ratings
Compare with other drugs.
| |||||||||
May reduce IOP by increasing uveoscleral outflow.
Indications and Usage
Reduction of IOP in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering agents or insufficiently responsive to other IOP-lowering medications.
Contraindications
Standard considerations; pregnancy.
Dosage and Administration
AdultsOphthalmic Instill 1 drop in affected eye(s) in evening.
Storage/Stability
Store at controlled room temperature. Keep container tightly closed.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Cardiovascular
Angina pectoris; bradycardia; chest pain; hypertension; hypotension.
CNS
Anxiety; depression; headache.
EENT
Ocular and conjunctival hyperemia; decreased visual acuity; eye discomfort and disorder; foreign body sensation; pain; pruritus; abnormal vision; blepharitis; blurred vision; cataract; conjunctivitis; dry eye; flare; iris discoloration; keratitis; lid margin crusting; photophobia; subconjunctival hemorrhage; tearing; sinusitis.
GI
Dyspepsia; GI disorder.
Genitourinary
Prostate disorder; urinary incontinence; UTI.
Metabolic
Hypercholesterolemia.
Respiratory
Bronchitis.
Miscellaneous
Arthritis; back pain; cold symptoms; infection; pain.
Precautions
Pregnancy
Category C .
Lactation
Undetermined.
Children
Safety and efficacy not established.
Active intraocular inflammation
Use with caution in patients with iritis/uveitis.
Bacterial keratitis
Bacterial keratitis has been reported with multiple-dose containers as a result of patient contamination.
Contact lenses
Remove contact lenses prior to and 15 min following administration.
Macular edema
Use with caution in aphakic patients, pseudophakic patients with a risk of torn posterior lens capsule, or in patients with risk factors for macular edema.
Pigmentation changes
Permanent changes to pigmented tissue may occur, most frequently involving pigmentation of the iris and eyelid and increased pigmentation and growth of eyelashes. Gradual change in eye color (ie, increased amount of brown pigmentation in the iris) may occur.
Patient Information
- Warn patient to not instill more often than once a day in the evening. More frequent use may decrease effectiveness of the medication.
- Teach patient proper technique for instilling eye drops. Wash hands; do not allow dropper to touch eye. Tilt head back, look up; pull lower eyelid down; instill drop. Close eye for 1 to 2 min and apply gentle pressure to bridge of nose. Do not rub eye.
- Advise patients who wear contact lenses to remove lenses before instilling this medicine and to wait at least 15 min after instilling eye drop before inserting lenses.
- Advise patient that if more than 1 topical ophthalmic drug is being used, administer the drugs at least 5 min apart.
- Inform patient that this medication may cause a gradual increase in brown pigment in the pupil, which may slowly change eye color.
- Inform patient that this medication may also cause eyelid skin darkening and increases in length, thickness, color, and number of eyelashes.
- Advise patient to contact eye doctor if eye or eyelid inflammation is noted, if eye is injured, or if having surgery on the eye.
- Remind patient that eye examinations and measurement of IOP are necessary while using this medication; advise patient to keep appointments.
 |
Link to Page |  |
Print Page |  |
Email Page |  | Add to List |
More Travoprost resources
travoprost ophthalmic Drug Interactions
Compare Travoprost with other medications for the treatment of:
Glaucoma, Open Angle, Intraocular Hypertension
